


**Brilliant Violet 421™ anti-mouse IL-33Rα (IL1RL1, ST2)**

**Catalog # / Size:** 1326545 / 50 µg  
**Clone:** DIH9  
**Isotype:** Rat IgG2a, κ  
**Immunogen:** IL-33Rα-hFcγ1 fusion protein.  
**Reactivity:** Mouse  
**Preparation:** The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 421™ and unconjugated antibody.  
**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).  
**Concentration:** Lot-specific



Mouse Th2 clone D10.G4.1 was stained with anti-mouse IL-33Rα/ST2 (clone DIH9) Brilliant Violet 421™ (filled histogram) or rat IgG2a, κ Brilliant Violet 421™ isotype control (open histogram).

**Applications:**

**Applications:** Flow Cytometry  
**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 microg per million cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

**Application References:** 1. Hashiguchi M, *et al.* 2014. *Eur. J. Immunology*. (FC) [PubMed](#)

**Description:** IL-33Rα, also known as ST2 or IL-1RL1, is a member of the Toll/IL-1 receptor family. It binds IL-33 and is structurally similar to IL-1R1. Two forms of the protein exist - a soluble form known as ST2 and a membrane anchored form known as ST2L. The membrane form is expressed by Th2 cells and bone marrow derived mast cells, whereas the soluble form is expressed by serum-stimulated fibroblasts.

Blocking with anti-ST2 antibodies has been shown to alleviate experimental

arthritis and airway inflammation. The IL-33-ST2 axis has been reported to be important across a range of diseases including asthma, allergies, and cardiac disease.

**Antigen  
References:**

1. Yanagisawa K, *et al.* 1993. *FEBS Lett.* 318:83.
2. Schmitt E, *et al.* 1990. *Cytokine* 6:407.
3. Yanagisawa K, *et al.* 1992. *FEBS Lett.* 302:51.
4. Takagi T, *et al.* 1993.